---
document_datetime: 2025-12-29 08:00:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/apealea.html
document_name: apealea.html
version: success
processing_time: 0.1287118
conversion_datetime: 2025-12-31 05:19:40.127539
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Apealea

[RSS](/en/individual-human-medicine.xml/66584)

##### Withdrawn

This medicine's authorisation has been withdrawn

paclitaxel Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Apealea](#news-on)
- [More information on Apealea](#more-information-on-apealea-730)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 February 2024, the European Commission withdrew the marketing authorisation for Apealea (paclitaxel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Inceptua AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Apealea was granted marketing authorisation in the EU on 20 November 2018 for the treatment of ovarian cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2023.

Therapeutic alternatives are available throughout the European Union. Patients taking Apealea or participating in a clinical trial are advised to consult their doctor.

The European Public Assessment Report (EPAR) for Apealea is updated to indicate that the marketing authorisation is no longer valid.

Apealea : EPAR - Medicine overview

Reference Number: EMA/791927/2018

English (EN) (177.91 KB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/overview/apealea-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-998)

български (BG) (235.07 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/bg/documents/overview/apealea-epar-medicine-overview_bg.pdf)

español (ES) (182.51 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/es/documents/overview/apealea-epar-medicine-overview_es.pdf)

čeština (CS) (215.09 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/cs/documents/overview/apealea-epar-medicine-overview_cs.pdf)

dansk (DA) (174.22 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/da/documents/overview/apealea-epar-medicine-overview_da.pdf)

Deutsch (DE) (189.4 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/de/documents/overview/apealea-epar-medicine-overview_de.pdf)

eesti keel (ET) (160.28 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/et/documents/overview/apealea-epar-medicine-overview_et.pdf)

ελληνικά (EL) (241.88 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/el/documents/overview/apealea-epar-medicine-overview_el.pdf)

français (FR) (184.51 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fr/documents/overview/apealea-epar-medicine-overview_fr.pdf)

hrvatski (HR) (206.03 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hr/documents/overview/apealea-epar-medicine-overview_hr.pdf)

italiano (IT) (178.14 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/it/documents/overview/apealea-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (214.01 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lv/documents/overview/apealea-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (210.17 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lt/documents/overview/apealea-epar-medicine-overview_lt.pdf)

magyar (HU) (213.71 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hu/documents/overview/apealea-epar-medicine-overview_hu.pdf)

Malti (MT) (222.17 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/mt/documents/overview/apealea-epar-medicine-overview_mt.pdf)

Nederlands (NL) (181.29 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/nl/documents/overview/apealea-epar-medicine-overview_nl.pdf)

polski (PL) (214.94 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pl/documents/overview/apealea-epar-medicine-overview_pl.pdf)

português (PT) (183.78 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pt/documents/overview/apealea-epar-medicine-overview_pt.pdf)

română (RO) (219.17 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/ro/documents/overview/apealea-epar-medicine-overview_ro.pdf)

slovenčina (SK) (212.26 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sk/documents/overview/apealea-epar-medicine-overview_sk.pdf)

slovenščina (SL) (206.44 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sl/documents/overview/apealea-epar-medicine-overview_sl.pdf)

Suomi (FI) (170.95 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fi/documents/overview/apealea-epar-medicine-overview_fi.pdf)

svenska (SV) (174.94 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sv/documents/overview/apealea-epar-medicine-overview_sv.pdf)

Apealea : EPAR - Risk-management-plan summary

English (EN) (525.76 KB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/rmp-summary/apealea-epar-risk-management-plan-summary_en.pdf)

## Product information

Apealea : EPAR - Product information

English (EN) (1.99 MB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/product-information/apealea-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-178)

български (BG) (2.46 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/bg/documents/product-information/apealea-epar-product-information_bg.pdf)

español (ES) (554.51 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/es/documents/product-information/apealea-epar-product-information_es.pdf)

čeština (CS) (2.68 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/cs/documents/product-information/apealea-epar-product-information_cs.pdf)

dansk (DA) (2.16 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/da/documents/product-information/apealea-epar-product-information_da.pdf)

Deutsch (DE) (2.25 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/de/documents/product-information/apealea-epar-product-information_de.pdf)

eesti keel (ET) (2.06 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/et/documents/product-information/apealea-epar-product-information_et.pdf)

ελληνικά (EL) (2.41 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/el/documents/product-information/apealea-epar-product-information_el.pdf)

français (FR) (2.38 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fr/documents/product-information/apealea-epar-product-information_fr.pdf)

hrvatski (HR) (2.16 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hr/documents/product-information/apealea-epar-product-information_hr.pdf)

íslenska (IS) (2.12 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/is/documents/product-information/apealea-epar-product-information_is.pdf)

italiano (IT) (2.1 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/it/documents/product-information/apealea-epar-product-information_it.pdf)

latviešu valoda (LV) (2.4 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lv/documents/product-information/apealea-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.4 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lt/documents/product-information/apealea-epar-product-information_lt.pdf)

magyar (HU) (2.36 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hu/documents/product-information/apealea-epar-product-information_hu.pdf)

Malti (MT) (2.76 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/mt/documents/product-information/apealea-epar-product-information_mt.pdf)

Nederlands (NL) (2.05 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/nl/documents/product-information/apealea-epar-product-information_nl.pdf)

norsk (NO) (2.32 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/no/documents/product-information/apealea-epar-product-information_no.pdf)

polski (PL) (2.21 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pl/documents/product-information/apealea-epar-product-information_pl.pdf)

português (PT) (2.07 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pt/documents/product-information/apealea-epar-product-information_pt.pdf)

română (RO) (2.27 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/ro/documents/product-information/apealea-epar-product-information_ro.pdf)

slovenčina (SK) (2.35 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sk/documents/product-information/apealea-epar-product-information_sk.pdf)

slovenščina (SL) (2.22 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sl/documents/product-information/apealea-epar-product-information_sl.pdf)

Suomi (FI) (2.17 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fi/documents/product-information/apealea-epar-product-information_fi.pdf)

svenska (SV) (2.16 MB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sv/documents/product-information/apealea-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0017 11/09/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Apealea : EPAR - All authorised presentations

English (EN) (39.65 KB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-565)

български (BG) (67.58 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/bg/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.13 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/es/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_es.pdf)

čeština (CS) (57.45 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/cs/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.73 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/da/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.75 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/de/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.92 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/et/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.42 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/el/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_el.pdf)

français (FR) (40.51 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fr/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.09 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hr/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.15 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/is/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.25 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/it/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.39 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lv/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.79 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/lt/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.38 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/hu/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.71 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/mt/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.76 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/nl/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.4 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/no/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.91 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pl/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.17 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/pt/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.15 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/ro/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.9 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sk/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (47.79 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sl/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40.4 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/fi/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (41.66 KB - PDF)

**First published:**

05/12/2018

**Last updated:**

06/03/2024

[View](/sv/documents/all-authorised-presentations/apealea-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Apealea Active substance paclitaxel International non-proprietary name (INN) or common name paclitaxel Therapeutic area (MeSH) Ovarian Neoplasms Anatomical therapeutic chemical (ATC) code L01CD01

### Pharmacotherapeutic group

- Antineoplastic agents
- Taxanes

### Therapeutic indication

Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum?sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

## Authorisation details

EMA product number EMEA/H/C/004154 Marketing authorisation holder

Inceptua AB

Gustavslundsv. 143

Opinion adopted 20/09/2018 Marketing authorisation issued 20/11/2018 Withdrawal of marketing authorisation 09/02/2024 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Apealea : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (323.47 KB - PDF)

**First published:** 10/05/2019

**Last updated:** 06/03/2024

[View](/en/documents/procedural-steps-after/apealea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Apealea-H-C-PSUSA-00002264-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/637582/2019

English (EN) (157.92 KB - PDF)

**First published:** 27/11/2019

**Last updated:** 06/03/2024

[View](/en/documents/scientific-conclusion/apealea-h-c-psusa-00002264-201812-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Apealea : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex I

English (EN) (239.75 KB - PDF)

**First published:** 27/11/2019

**Last updated:** 06/03/2024

[View](/en/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (434.12 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/bg/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_bg.pdf)

español (ES) (191.87 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/es/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_es.pdf)

čeština (CS) (444.95 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/cs/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_cs.pdf)

dansk (DA) (177.85 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/da/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_da.pdf)

Deutsch (DE) (190.55 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/de/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_de.pdf)

eesti keel (ET) (218.38 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/et/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_et.pdf)

ελληνικά (EL) (471.93 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/el/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_el.pdf)

français (FR) (188.59 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/fr/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_fr.pdf)

hrvatski (HR) (418.1 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/hr/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_hr.pdf)

íslenska (IS) (173.42 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/is/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_is.pdf)

italiano (IT) (195.74 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/it/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_it.pdf)

latviešu valoda (LV) (447.64 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/lv/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_lv.pdf)

lietuvių kalba (LT) (489.13 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/lt/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_lt.pdf)

magyar (HU) (350.76 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/hu/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_hu.pdf)

Malti (MT) (425.1 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/mt/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_mt.pdf)

Nederlands (NL) (185.63 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/nl/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_nl.pdf)

norsk (NO) (170.47 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/no/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_no.pdf)

polski (PL) (448.41 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/pl/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_pl.pdf)

português (PT) (182.18 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/pt/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_pt.pdf)

română (RO) (436.96 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/ro/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_ro.pdf)

slovenčina (SK) (418.8 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/sk/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sk.pdf)

slovenščina (SL) (429.83 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/sl/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sl.pdf)

Suomi (FI) (177.24 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/fi/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_fi.pdf)

svenska (SV) (173.26 KB - PDF)

**First published:**

27/11/2019

**Last updated:**

06/03/2024

[View](/sv/documents/scientific-conclusion/apealea-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sv.pdf)

## Initial marketing authorisation documents

Apealea : Orphan designation withdrawal assessment report (initial authorisation)

Reference Number: EMA/COMP/138404/2016

English (EN) (471.85 KB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/orphan-maintenance-report/apealea-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Apealea : EPAR - Public assessment report

Reference Number: EMA/CHMP/785964/2018

English (EN) (10.03 MB - PDF)

**First published:** 05/12/2018

**Last updated:** 06/03/2024

[View](/en/documents/assessment-report/apealea-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Apealea

Adopted

Reference Number: EMA/CHMP/474774/2018

English (EN) (117.88 KB - PDF)

**First published:** 21/09/2018

**Last updated:** 06/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-apealea_en.pdf)

#### News on Apealea

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018) 21/09/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### More information on Apealea

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-06-422) on 18 December 2006.

Apealea was withdrawn from the Community register of orphan medicinal products in July 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 06/03/2024

## Share this page

[Back to top](#main-content)